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Project 1: 1,8-Naphthyridine Analog Binding Model 
 G-protein coupled receptors (GPCRs) are transmembrane receptors found in 
eukaryotes that control many cellular signaling events.  The cannabinoid receptors, CB1 
and CB2, are both GPCRs.  These are the receptors that are activated by Δ9-THC, the 
principal psychoactive compound in marijuana.  CB1 is found mainly in neuronal cells 
and its activation is thought to lead to the negative, psychoactive side effects of 
marijuana.  CB2 is found in immune cells and in small concentrations in brain tissue.  
Beneficial effects of activating the cannabinoid receptors include reduction in intraocular 
pressure, analgesia, antiemesis, and effects on bone density.  Designing a drug that can 
selectively activate CB2, without activating CB1 should lead to analgesia without the 
negative side effects of CB1.  Recent studies have shown the potential of CB2 in treating 
neurodegenerative diseases such as Parkinson’s and Alzheimer’s; increasing the 
importance for developing CB2 selective drugs.  Analogs were developed using the 1,8-
naphthyridine scaffold  that are selective for CB2.  These analogs had different activities 
at CB2 based on their structures.  One goal of my thesis project was to develop a model 
for the binding of 1,8-naphthyridine analogs binding at CB2 and to develop a hypothesis 
concerning the structural requirements for their production of agonism or antagonism at 
CB2.  The analogs were synthesized and tested by our collaborator, Dr. Clementina 
Manera at the University of Pisa.  Computational modeling techniques were used to 
generate conformations of the 1,8-naphthyridine compounds.  An automated docking 
program, Glide, was used to generate the ligand-receptor complexes.  The model showed 
that the presence of a substituent at the C-6 position of the 1,8-naphthyridine ring 
prevents CB2 from adopting an activated state. 
Project 2: Aminoalkylindole Pharmacophore Model 
 A second goal of my thesis was to develop a pharmacophore model for the newly 
discovered aminoalkylindole (AAI) receptor.  WIN 55212-2 is the prototypical 
aminoalkylindole (AAI) and is known to act as an agonist at both CB1 and CB2.  
Recently, our collaborator, Dr. Nephi Stella (University of Washington) discovered that 
WIN 55212-2 and other AAI compounds bind to a non-CB GPCR found in HEK 293 and 
T98G cells.  AAI analogs were developed to generate a structure activity relationship 
(SAR).  These analogs and their binding data were used to generate a pharmacophore 
model that explains how these AAI compounds are binding to this new receptor.  A 
pharmacophore model is a set of chemical features and their spatial arrangement that 
explains how a set of compounds bind to a protein.  Computational modeling techniques 
were used to generate conformations of the AAI compounds.  The pharmacophore model 
was developed in PHASE (Schrodinger, Inc.) using a conformational approach on a set of 
active compounds.  The pharmacophore model shows the importance of four aromatic 
features, a hydrogen bond acceptor feature, and a hydrophobic feature corresponding to 
the C-2 position of the indole ring. 
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CHAPTER I 
INTRODUCTION 
 
 
The Cannabinoid Receptors 
The cannabinoid CB1 and CB2 receptors belong to the Class A (rhodopsin (Rho) 
family) of G-protein coupled receptors (GPCRs).  CB1 was initially cloned from a rat 
cerebral cortex cDNA library [1].  CB1 was found to be in the brain at multiple locations 
including, the hippocampus, cerebellum, and substantia nigra [2].  The second 
cannabinoid receptor sub-type, CB2 was cloned from a human promyelocytic leukemia 
cell HL60 cDNA library.  This receptor was shown to have high density in peripheral 
tissue.  More specifically, CB2 is located on macrophages and several other immune cells 
[3].  Because CB1 is found mostly in the brain it is thought to mediate the negative, 
psychoactive effects of cannabinoid ligands.  Recent studies have implicated CB2 in 
neurodegenerative disease states, such as Alzheimer’s, Huntington’s disease and 
Parkinson’s disease [4].  CB2 has also been shown to be expressed in high levels in 
cancer cells and CB2 activation induces tumor apoptosis [5].  These developments show 
the importance of efforts in finding CB2 selective ligands to possibly treat these diseases. 
 CB1 and CB2 are Class A G-protein coupled receptors (GPCRs) which act via 
Gi/o proteins [6].  Activation of Gi/o proteins results in inhibition of adenylyl cyclase, 
2 
 
which ultimately reduces cyclic AMP levels [6].  The classical model of GPCR function 
states that once the receptor is activated a heterotrimeric (α, β, and γ subunits) G-protein 
will couple with the receptor.  Insertion of the α5 helix of the Gα subunit results in the 
exchange of GDP for GTP.  GTP binding is followed by dissociation of the β and γ 
subunits from the α subunit, but the β and γ subunits stay together [7].  The β and γ 
complex and the α subunit cause downstream effects by interacting with other proteins.  
Once the signaling event has occurred, the receptor needs to be removed from the cell 
surface so that it does not continue to signal.  The cell does this by phosphorylating serine 
and threonine residues on the C-terminus of the receptor with GPCR kinases (GRKs). 
The phosphorylated C-terminus can interact with β-arrestin proteins that cause the 
receptor to be internalized via clathrin coated pits [8].  This internalization stops the 
receptor from being able to signal. 
The crystal structures of Class A GPCR’s like rhodopsin [9], β2-adrenergic 
receptor [10], sphingosine 1- phosphate receptor [11], and the opioid receptors [12, 13] 
show these types of receptors have four similar structural features.  These similar 
structural features are: seven transmembrane helices, an extracellular N-terminus, an 
intracellular C-terminus, and extracellular and intracellular loops that connect the helices.  
Figure 1 shows an image of CB2 in a lipid bilayer with the Gi G-protein inserted. 
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Figure 1. CB2 in Complex with the Gi G-protein in a Lipid Bilayer.  CB2 is in 
orange, heterotrimeric G-protein is in green, cyan, and magenta [14]. 
 
 
CB2 activation requires the completion of several important steps that are similar 
to many class A GPCRs.  In the inactive state of CB2 W6.48 has it’s χ1 dihedral in a g+ 
(-60°) conformation and F3.36 has it’s χ1 dihedral in a trans (180°) conformation.  W6.48 
and F3.36 are important residues known as the “toggle switch” residues.  Another pair of 
important residues are R3.55 and D6.30, these are known as the ionic lock residues.  In 
the inactive state of the receptor R3.55 and D6.30 form a salt bridge with each other to 
hold the intracellular end of the receptor closed to G-protein insertion.  Once activated, 
the “toggle switch” residues, W6.48 and F3.36 must switch positions.  W6.48 undergoes 
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a χ1 g+ (-60°)  trans (180°) dihedral transition and F3.36 undergoes a χ1 trans (180°) 
 g+ (-60°) dihedral transition.  Figure 2 shows the positions of W6.48 and F3.36 in 
inactive and active states of CB2.  These transitions induce a conformational change in 
the CWXP flexible hinge region of transmembrane helix 6 (TMH6) that causes TMH6 to 
straighten and move its intracellular end away for the TMH bundle.  The movement of 
the intracellular end of TMH 6 away from the bundle causes the salt bridge between the 
ionic lock residues R3.55 and D6.30 to break [15], allowing the intracellular side of the 
receptor to open for G-protein insertion.  Figure 3 shows the distance between TMH3 and 
TMH6 upon activation of CB2.  A ligand that is able to block the transition of W6.48 
from g+ to trans would ultimately block the G-protein from coupling.  Such a ligand 
would be considered an antagonist. 
 
 
Figure 2. A) Toggle Switch Residues in Inactive State of CB2. W6.48 χ1 in g+ 
and F3.36 χ1 in trans. B) Toggle Switch Residues in Active State of CB2.  W6.48 χ1 in 
trans and F3.36 χ1 in g+. [15].  W6.48 is shown in orange and F3.36 is shown in 
magenta. 
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Figure 3. Ionic Lock Residues in Inactive and Active State of CB2.  In the active 
state R3.55 and D6.30 form a salt bridge.  In the active state R3.55 and D6.30 are too far 
apart to form a salt bridge. [15]. 
 
 
Cannabinoid Ligands 
 Cannabinoid agonists are grouped into four different classes: classical, non-
classical, aminoalkylindole, and eicosanoid.  The classical group is composed of 
compounds similar to Δ9-THC (1, Ki CB1=5.05 nM and Ki CB2=80.3 nM), which are 
dibenzopyran derivatives.  A high affinity ligand from this class is HU-210 (2), which has 
higher affinity for CB1 and CB2 than Δ9-THC (Ki CB1 0.06 nM and Ki CB2 0.17 nM).  
The non-classical group has compounds that are Δ9-THC analogs, but lack the pyran ring.  
The prototype from this group is CP-55940 (3), which was developed by Pfizer in 1974 
[16] (Ki CB1 0.5 nM and Ki CB2 0.69 nM).  The aminoalkylindoles are structurally 
dissimilar to the classical and non-classical group, having an indole ring with different 
substituents at N-1 and C-2 positions.  The prototypical aminoalkylindole is (R+) WIN 
55212-2 (4, Ki CB1 1.89 nM and Ki CB2 0.28 nM).  The eicosanoids are best 
exemplified by the two fatty acid derived, endogenous ligands anandamide (5, AEA) (Ki 
CB1 61 nM and Ki CB2 279 nM) discovered in 1992 [17] and 2-arachidonylglycerol (6, 
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2-AG) (Ki CB1 58.3 nM and Ki CB2 145 nM) discovered in 1995 [18].  CB1 and CB2 
Ki values taken from Pertwee et al. 2010 review [19].  The compound ajulemic acid 
(AJA), a synthetic analog of a THC metabolite, Δ9-THC -11-oic acid, provided an agonist 
that was selective for CB2 over CB1 and that produced anti-inflammatory, analgesic, and 
antitumor effects[20, 21].  This showed the potential benefit of creating ligands that can 
selectively activate CB2 over CB1. 
 
    
  1        2  
     
  3       4 
 
    
               5         6 
Figure 4. Chemical Structures of Cannabinoid Receptor Agonists. 
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 Two important selective antagonists were developed in the 1990s.  SR141716A 
(7) was developed in 1994 as a CB1 selective antagonist (Ki CB1 1.8 nM and Ki CB2 
514 nM).  SR144528 (8) was developed in 1998 as a selective CB2 antagonist (Ki CB1 
500 nM and Ki CB2 0.28 nM).  These selective antagonists helped distinguish the roles 
of CB1 and CB2 and which compounds were active at which receptor sub-type.  
Subsequently, JTE-907 (9, Ki CB1 2370 nM and Ki CB2 35.9 nm), a selective CB2 
antagonist was developed.  JTE-907 contains a quinoline central ring with an amide 
group at position 3, similar to the SR compounds [22].  The structure of JTE-907 has 
inspired analogs with a 1,8 naphthyridine ring instead of an quinoline ring.  Such 1,8 
naphthyridine analogs are a topic in this thesis. 
     
  7       8 
     
  9      1,8-Naphthyridine Scaffold 
Figure 5. Chemical Structures of Cannabinoid Receptor Antagonists and 1,8- 
Naphthyridine Scaffold. 
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Project 1: 1,8-Naphthyridine Binding Data 
 In a collaborative project with the Reggio Lab, Dr. Clementina Manera’s group 
recently produced SAR data for analogs from the 1,8-naphthyridin-2(1H)-on-
carboxamide scaffold binding to CB2 (unpublished).  The goal of this project was to 
produce CB2 selective ligands from the 1,8-naphthyridine scaffold.  Over 20 compounds 
were synthesized to test the significance of substituents at positions N-1 and C-6 on the 
naphthyridine ring.  Seven CB2 selective compounds (A1, A2, 5, 17, 20, 21, and 26) 
were tested for their ability to recruit β-arrestin and change cAMP levels.  These seven 
compounds are shown in Figure 6.  β-arrestin 2 assays showed of the seven compounds 
tested that four were agonists and three were antagonists/inverse agonists.  WIN55212-2, 
a CB2 agonist, and SR144528, a CB2 antagonist were used as reference ligands.  It was 
seen that compounds A1, A2, 5 and 17 were able to recruit β-arrestin 2 in the same 
manner as WIN55212-2, thus assigning them as agonists.  Compounds 20, 21, and 26 
were able to block β-arrestin 2 recruitment in the same manner as SR144528, thus 
assigning them as antagonists/inverse agonists.  Some assays were inconclusive because 
compounds 5, 20, and 26 were insoluble under the test conditions.  For compounds A1, 
A2, and 17 it was seen that cAMP levels decrease in a dose dependent manner, which is 
consistent with agonist activity.  Compound 21 was shown to inhibit WIN55212-2 in a 
dose dependent manner, which is consistent with antagonist activity.  The ligands with 
substituents at position C-6 were seen to be antagonists/inverse agonists.  Table 3 in 
Appendix 2 shows the compounds used to develop the binding model along with CB2 
binding affinities and activity data. 
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10 
 
 
 26 
Figure 6. 1,8-Naphthyridine Agonists and Antagonists 
 
 
Project 2: The Aminoalkylindoles 
 The aminoalkylindole (AAI) pravadoline was developed in hopes of producing a 
non-acidic non-steroidal anti-inflammatory drug (NSAID) that would lack negative 
gastrointestinal side effects [23].  In this process, it was discovered that pravadoline 
inhibits prostaglandin synthesis, a characteristic of other NSAIDs; and showed 
antinociception capabilities in rodent assays.  Other AAI analogs showed antinociception 
activity in rodent assays, but did not inhibit prostaglandin synthesis, meaning they are 
producing antinociceptive effects by a different mechanism than NSAIDs.  These AAI 
compounds and pravadoline were tested for their ability to inhibit electrically stimulated 
contractions of mouse vas deferens (MVD) preparations, an assay at which both opiod 
and cannabinoid receptors are active.  It was found that pravadoline and these select 
analogs did have activity in the MVD assays, but this activity was not inhibited by the 
opioid antagonist naloxone. So, some AAIs have antinociceptive activity, but do not 
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inhibit prostaglandin synthesis or bind to the opioid receptors [24].  Shortly afterwards, 
the AAIs were found to inhibit adenylyl cyclase by acting through a Gi protein [25].  
Along with many other GPCRs, the cannabinoid receptors produce effects mediated by 
Gi coupling [26].  AAI activity was tested at a number of different receptors thought to 
be capable of producing antinociceptive effects.  It was found that AAIs do not act 
through opioid, purinergic, adrenergic, γ-aminobutyric acid, 5-HT, neurokinin, 
bradykinin, and prostanoid receptors [27].  This same study showed that AAIs have a 
similar profile as levonantradol, a cannabinoid agonist.  It was soon found that AAIs act 
as agonists at the cannabinoid receptor [28, 29].  These experiments showed that the AAI, 
WIN55212-2 had the highest affinity for the cannabinoid receptor of all the AAIs.  Once 
the CB2 receptor was discovered and cloned, it was shown that WIN55212-2 had a 
slightly higher affinity for CB2 than for CB1 [30]. 
 
Figure 7. WIN 55212-2 s-cis and s-trans conformations 
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 Bell et al. reported in 1991 the two important conformations, s-cis and s-trans, 
which AAI compounds can have due to positioning of the 3-naphthyl group [24].  Figure 
7 shows the s-cis and s-trans conformation for WIN 55212-2.  The s-cis conformation has 
the naphthyl group over the 6 membered ring of the indole and s-trans conformation has 
the naphthyl over the C-2 position of the indole.  Conformational analysis of the AAI 
showed that when there is a methyl at the C-2 position the s-cis conformation is the lower 
energy conformation, but when there is a hydrogen at C-2 the s-trans conformation is 
lower in energy.  Reggio et al. performed conformational analyses and receptor model 
docking studies of WIN 55212-2.  These studies suggested that although the s-cis 
conformation of WIN 55212-2 is lower in energy, it is the s-trans conformation that is the 
preferred conformation for CB1 and CB2 [31].  These docking studies also suggested that 
the carbonyl group in WIN 55212-2 was not a receptor interaction site.  To this this, they 
synthesized rigid (E)- and (Z)-naphthylidene indene analogs.  The (E) isomer mimics the 
s-trans conformation and the (Z) isomer mimics the s-cis conformation.  In these analogs, 
the carbonyl group has been removed and a double bond (cis or trans) has been 
incorporated in this region of the molecule.  Binding studies of these analogs showed that 
the E-indenes had higher affinity for the CB1 and CB2.  The (E) C2- H indene had a CB1 
Ki of 2.72 nM and a CB2 Ki of 2.72 nM.  The (E) C2-Me indene had a CB1 Ki of 2.89 
nM and a CB2 Ki of 2.05 nM.  The (Z) C-2 H indene had a CB1 Ki of 148 nM and a CB2 
Ki of 132 nM.  The (Z) C-2 Me indene had a CB1 Ki of 1945 nM and a CB2 Ki of 658 
nM.   These results also suggest that the carbonyl oxygen of the AAI’s is not necessary 
for binding to the CB receptors.  Reggio et al. reported that the most significant 
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interactions of WIN 55212-2 at the CB receptors were aromatic stacking interations in 
the TMH4-5-6 aromatic cluster region in CB1/CB2 [31].  Figure 8 shows the Z and E C-2 
H indenes.  Figure 9 shows the Z and E C-2 Me indenes. 
 
Figure 8. C-2 H (Z) and (E) indenes. 
 
Figure 9. C-2 Me (Z) and (E) indenes 
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Data for WIN55212-2 binding to a non-cannabinoid receptor has been available 
for over 10 years.  A study done in 1997 compared WIN 55212-2 binding in rat 
cerebellar membrane to neuroblastoma×glioma hybrid NG108-15 membranes (these 
latter membranes contain a low concentration of CB receptors).  This study showed that 
known cannabinoid ligands did not displace [3H]WIN55212-2 in NG108-15 membranes.  
Specifically, 5 µM of CP 55940 and AEA displaced only 15 % of [H3]WIN55212-2 in 
these preparations.  In rat cerebellar membranes (which contain a higher concentration of 
CB1 receptors), CP 55940 and AEA had IC50 values of 1 nM and 300 nM, respectively 
[32].  This same study showed that at 1 µM of Δ9-THC or levonantradol did not displace 
[3H]WIN55212-2 in NG108-15 membranes.  While, other AAI analogs did displace 
[3H]WIN55212-2 in NG108-15 membranes.  This study concluded that there is a non-
cannabinoid receptor found in NG108-15 cell membranes that selectively binds AAI 
ligands. 
 Ultimately, WIN 55212-2 has been shown to bind also to non-CB receptor [19, 
33].  In collaboration with Dr. Nephi Stella’s lab (from the University of Washington), 
the binding of WIN 55212-2 and other AAIs binding to a non-CB receptor is explored in 
this thesis. 
Aminoalkylindole Binding Data 
A collaborator of the Reggio Lab, Dr. Nephi Stella and his group have produced 
data showing WIN 55212-2 and other AAIs have activity in vitro at non-CB receptors in  
human embryonic kidney cells (HEK293) and astrocytoma cells (T98G) (unpublished).  
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The first interesting piece of evidence is mRNA data showing that neither cannabinoid 
receptors are present in HEK293 cells.  This agrees with another experiment using 
microarray techniques to measure mRNA levels for hundreds of GPCRs in HEK293 cells 
[34].  These studies show that both cannabinoid receptors are not significantly expressed 
endogenously in HEK293 cells.  WIN55212-2 displaces [3H]WIN55212-2 in radioligand 
binding assays in untransfected HEK293 cells, while other known cannabinoid ligands do 
not.  The ligands tested were Δ9-THC, cannabidiol, cannabichromin, cannabinol, 
cannabigerol, HU-210, O-2050, SLV319, SR144528, AM630.  Another piece of evidence 
showing non-CB receptors in HEK293 cells is that CP55940, a high affinity ligand for 
both CB receptors, SR141716, a high affinity CB1 ligand, and SR144528, a high affinity 
CB2 ligand, all do not displace [3H]CP55940 in untransfected HEK293 cells.  
Experiments were done to rule out other receptor targets genetically related to the CB 
receptors that have been known to bind cannabinoid ligands.  These experiments ruled 
out GPRs 3,6,12, 18, 35, 40, 55, and 120.  Other receptors that were ruled out were 5-HT, 
β-adrenergic, TRPV1, LPA, P2Y, and S1P.  All of this data points to the notion that there 
are AAI sensitive receptors that are non-CB receptors in HEK293 cells.  To determine if 
these receptors are GPCR’s a [35S]GTPγS binding assay was performed.  [35S]GTPγS is a 
non-hydrolyzable form of GTP, so when it binds to the Gα subunit it will not be 
hydrolyzed back to GDP by GTPase.  An increase in [35S]GTPγS binding means the 
receptors are undergoing the GDP to GTP exchange. So these receptors are GPCRs.  It 
was shown that AAI compounds increase [35S]GTPγS binding in non-transfected 
HEK293 cells, suggesting that the non-CB site WIN 55212-2 binding site is a GPCR.  
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Pertussis toxin is used to determine if a GPCR couples to Gi/o proteins.  Pertussis toxin is 
known to inhibit any Gi/o proteins in the cell from binding to GPCRs via ADP-
ribosylation of the α subunit [35].  If a GPCR acts via Gi/o proteins, adding pertussis toxin 
will eliminate any signaling.  In this case pertussis toxin was shown to eliminate 
[35S]GTPγS binding, thus these AAI receptors are coupling to Gi/o proteins.  The CB 
antagonists SR141716 and SR144528 do not block GTPγS binding, further suggestin that 
these AAI receptors are not CB receptors.  In T98G cells it was shown that CP55940, 
SR141716A, and SR144528 do not displace [3H]WIN55212-2, but other AAI compounds 
do.  It was also seen in T98G cells that AAI compounds increase [35S]GTPγS binding and 
this binding is sensitive to pertussis toxin.  Overall, this data suggests that AAI 
compounds are binding to non-CB receptors that are GPCRs which act via Gi/o 
proteins in HEK293 and T98G cells.  Dr. Stella’s group developed AAI analogs and 
tested their binding in HEK293 cells and T98G cells.  We used this data to build a 
pharmacophore model for this non-CB AAI receptor.  Figure 10 shows the structures of 
some of the AAI compounds used in this thesis.  Table 4 in Appendix 2 shows the rest of 
the compounds used to develop a pharmacophore model and their binding affinities. 
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WIN 55212-2    CBX-003   CBX-006 
Figure 10. Structures of Some AAI Compounds 
 
 
 Dr. Stella’s group also used the previously mentioned, rigid (E)- and (Z)- indene 
analogs (Pages 13 and 14) to probe which conformation was active at the AAI binding 
sites.  The C2 methyl Z-Indene had a Ki of 466 nM, while the C2 methyl E-Indene had 
undetectable binding.  The C2 hydrogen Z-Indene had a Ki of 437 nM, while the C2 
hydrogen E-Indene had a Ki of 3.4 µM.  This data suggests that the (Z) isomer is 
preferred, thus the s-cis conformation is favored over the s-trans.   
 Dr. Stella’s lab tested AAI analogs to develop SAR data for binding to these 
novel receptors.  The SAR data showed that to bind to the AAI site the s-cis 
conformation is preferred, the accessibility of the carbonyl oxygen is important, the 
indole ring is important, and the naphthyl group is important.  From the SAR data Dr. 
Stella’s lab synthesized more AAI analogs to test, using these analogs and their binding 
data a pharmacophore model will be developed.  To characterize the binding site and how 
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the ligands bind, one goal of this thesis is to develop a pharmacophore model for the non-
CB AAI receptor.  The goal of this study is to develop a pharmacophore that can be used 
to generate more selective ligands for these sites and to further characterize the 
pharmacology of these receptors. 
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CHAPTER II 
GOALS AND METHODS 
 
 
Project Goals 
 There are two goals for this project. 1) Create a binding model that explains how 
the 1,8-naphthyrdine analogs developed by Dr. Manera bind to CB2.  2) Create a 
pharmacophore model hypothesis for aminoalkylindoles binding to a unique GPCR found 
in HEK 293 and T98G cells. 
Project 1: 1,8-Naphthyridine Binding Model Development 
 To help explain how these compounds are interacting with the receptor a docking 
study was performed using the automatic docking program Glide v5.8 (Schrodinger Inc., 
Portland, OR) [36, 37].  Before allowing Glide to dock the ligands, a thorough 
conformational search of each ligand was performed using Spartan ’08 (Wavefunction 
Inc., Irvine, CA).  All of the rotatable bonds in each ligand were identified and rotated 3-
8 fold.  A semi-empirical AM1 geometry optimization was performed on all of the 
conformers generated from these rotations.  After this initial geometry optimization all 
duplicates were deleted.  A more rigorous, ab initio geometry optimization was 
performed using Hartree-Fock level of theory at the 6-31G* level for A1, A2, 5, 17, and 
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26; and 6-311G* basis set was used for compounds 20 and 21 to account for the bromine 
atom. This identified the global minimum conformer for each ligand, which was used as 
the starting structure in Glide v5.8 for the docking process.   
 To generate the docked complexes, the ligands were first docked using interactive 
computer graphics into the CB2 model.  The CB2 model was pulled from molecular 
dynamics simulation of CB2 with its endogenous ligand 2-AG.  The agonists were 
docked into the active state model, which had the toggle switch residues in the 
appropriate conformations and the salt bridge between the ionic lock residues were 
broken.  The antagonists were docked into the inactive state model with an intact salt 
bridge and appropriate conformations for toggle switch residues.  The transmembrane 
helices were pulled apart and the ligands were placed into the active site.  The ligand-
receptor complexes were minimized using the OPLS2005 all atom force field in 
Macromodel 9.9 (Schrodinger Inc.).  Glide v5.8 was used to explore the other possible 
ligand conformations and receptor interactions using flexible docking.  Flexible docking 
allows Glide to translate the ligand in the receptor and rotate ligand dihedrals to find the 
best ligand conformation.  Certain residues were constrained to interact with the ligands. 
Based on mutation data [38], S7.39 was required to be in a hydrogen bonding interaction 
with the ligand and hydrophobic residues in contact with the ligand were noted as 
important interactions for the flexible docking. 
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Project 2: Pharmacophore Model Development for the AAI Receptor 
 A pharmacophore model is a set of chemical features and their spatial 
arrangements that describe how a set of ligands bind to a biological target.  To make a 
pharmacophore model a conformational search on active and inactive ligands must be 
performed to understand the conformational space the ligands are occupying.  A 
conformational search of subject AAI compounds was performed in Spartan ‘08 
(Wavefunction, Inc.).  All compounds were built in Spartan ‘08 and all the rotatable 
bonds were identified.  The bonds connecting both aromatic groups to the carbonyl 
carbon were set to an 8 fold rotation.  The rotatable bond connected to the N-1 position 
was set to a 2 fold rotation.  The next bond in the tail was set to a 3 fold rotation.  A 
geometry optimization of all of the conformers that were generated was performed in 
Spartan ‘08 using the semi-empirical AM1 level of theory.  After this, the conformers 
were examined to identify all unique conformations.  These unique conformers were used 
to further refine the conformational search via geometry optimizations at the Hartree-
Fock level 6-31G* level.  After this calculation was performed the duplicate conformers 
were deleted to leave only the unique conformations of the molecule.  These unique 
conformers were used to develop the pharmacophore model for aminoalkylindoles 
binding to the AAI sites using the program PHASE v3.4 (Schrodinger Inc., Portland, 
OR.) [39]. 
Before PHASE was used, as much information was gathered on what features of 
compounds appear to produce binding vs. what features appear to interfere with binding.  
22 
 
Based on the Indene binding data (see Page 17) it is clear that the bioactive conformation 
is the s-cis conformation.  The Z indenes bind with a higher affinity than the E-indenes, 
thus the s-cis conformation is preferred.  Also, based on the binding data for WIN 55212-
3, the S enantiomer, it is known that the N-1 tail prefers to be on one side of the indole 
ring.  This data was taken into consideration when developing the pharmacophore model 
in PHASE.  Only the s-cis conformers were put into PHASE, and any pharmacophore 
hypothesis generated with the N-1 tail on the wrong side of indole will not be considered. 
In PHASE, compounds with a Ki value under 5 nM were identified as active 
compounds.  This gave five compounds, WIN 55212-2, TK 18, CBX 003, CBX 004, and 
CBX 009 (see Appendix 2 Table 4) as active.  The pharmacophore model was generated 
from the s-cis conformation of these active compounds.  CBX 008 was assigned as 
inactive because of its high Ki value of 972 nM.  Chemical features were assigned to the 
ligands based on the algorithm PHASE uses.  The features are aromatic (R), hydrogen 
bond acceptor (A), hydrogen bond donor (D), hydrophobic (H), positive (P), and negative 
(N).  These features can be removed or features can be added.  PHASE assigned the 
nitrogen on the morpholino ring a positive (P) feature, meaning it will be protonated at 
physiological pH. However, the pKa of these compounds is in the range of 4.5-6.0 [28], 
so these compounds will not be protonated at physiological pH.  The positive feature on 
the morpholino nitrogen was therefore removed and was not used in generating the 
pharmacophore model.  All other features were left how PHASE assigned them.  All of 
the compounds had four aromatic features due to the two rings of the indole ring and the 
two rings of the naphthalene.  All compounds had a hydrogen bond acceptor feature due 
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to the carbonyl oxygen attached at C-3 of the indole ring.  All compounds had a 
hydrophobic feature at the N-1 tail, but these hydrophobic features were not in the same 
exact region of space for all compounds.  WIN 55212-2 had a hydrophobic feature 
shifted from the rest of the active compound’s N-1 hydrophobic feature.  This made it 
impossible for PHASE to incorporate a hydrophobic feature in the final pharmacophore 
model.  The maximum number of sites and the minimum number of sites was set to 6, so 
the model will have 6 features in it.  The common pharmacophore hypotheses were 
assigned to match all five active compounds.  To generate the common pharmacophore 
hypotheses PHASE uses a tree based partitioning technique using the intersite distances 
of pharmacophores.  The options of finding a common pharmacophore were left at their 
default values which are a minimum intersite distance of 2.0 Å, a maximum tree depth of 
5, an initial box size of 32.0 Å, and a final box size of 1.0 Å.  Once the common 
pharmacophore hypotheses were determined, a survival score was calculated for each.  
The survival score was used to rank the pharmacophore hypotheses.  The survival score 
involves the Reference_Score, a Volume_Score, a conformational energy factor, and how 
well the hypothesis matches a specified number of active compounds.  This survival 
score was further refined by assessing how well the hypothesis aligns to inactive 
compounds.  If an inactive compound aligns well, then the survival score is penalized.  A 
higher survival score corresponds to a better pharmacophore model and helps decide 
which hypothesis is the best model.  The pharmacophore model that was used had the 
highest survival score.
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CHAPTER III 
RESULTS 
 
 
Project 1: Conformational Analysis of 1,8-Naphthyridine Compounds 
The conformational search on the 1,8-naphthyridine compounds (see Appendix 2 
Table 3 for structures) revealed several key common features.  The 4-methyl cyclohexyl 
group attached to the amide gave rise to four positional isomers (see Figure 11).  There 
are two cis isomers and two trans isomers.  One cis isomer has the amide group 
positioned axial and the 4-methyl positioned equatorial.  The other cis isomer has the 
amide equatorial and the 4-methyl axial.  The two trans isomers have both groups 
positioned either axial or equatorial.  The lowest energy isomer is the trans isomer with 
both groups positioned equatorial.  The other trans isomer is 3.4 kcal/mol higher in 
energy.  The cis with the amide equatorial is 2.2 kcal/mol higher and the cis with the 
amide axial is only 1.1 kcal/mol higher in energy.  Manera et al. reported in 2009 that the 
cis isomer has a 0.7 nM affinity for CB2, while the trans isomer has a 9.0 nM affinity 
[40]. The lowest energy conformers with the 4-methyl cyclohexyl group positioned in a 
cis conformation with the amide group axial were used in this docking study.  Figure 11 
shows the four positional isomers and their relative energies for compound A.
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Figure 11. The Four Positional Isomers and Their Relative Energies for Compound A2 
 
 
 Another common feature for these ligands is that they all have an intramolecular 
hydrogen bond between the amide N-H and the carbonyl carbon on C-2 (see Appendix 2 
Table 3 for drawing).  For this hydrogen bond to be in place the amide group must be in 
plane with the naphthyridine ring.  If the amide is rotated 30 degrees out of plane, there is 
a significant energy increase of 2.0 kcal/mol.  To rotate the amide a full 90 degrees out of 
plane costs 8.14 kcal/mol.  It is important to know the energy cost associated with this 
rotation because it is unlikely that a docked conformation can have the amide rotated out 
of plane with the naphthyridine ring.  Any Glide result with the amide rotated out of 
plane can be discarded because of the high conformational cost associated with losing the 
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internal hydrogen bond.  Figures 12 and 13 show the global minima conformers for the 
agonists and antagonists, respectively. 
Compound 5 adopts a unique global minimum conformation due the 4-hydroxy 
butyl tail attached at N-1 (see Figure 12). The hydroxyl group is able to form an 
additional intramolecular hydrogen bond with the carbonyl oxygen at C-2.  To lose this 
additional internal hydrogen bond costs 1.5 kcal/mol. 
 
 
Figure 12. Structures of the Global Minima for 1,8-Naphthyridine Agonists.  The 
dotted line represents intramolecular hydrogen bonding. 
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Figure 13. Structures of the Global Minima for 1,8-Naphthyridine Antagonists.  
Compound 20 and 21 have a Br at C-6 and Compound 26 has a p-methoxyphenyl at C-6. 
The dotted line represents intramolecular hydrogen bonding. 
 
 
Docking Results of 1,8-Naphthyridine Compounds 
 The docking results for all of the compounds showed hydrogen bonds with both, 
K3.28 and S7.39.  K3.28 forms a hydrogen bond with the carbonyl oxygen on C-2 and 
S7.39 forms a hydrogen bond with the carboxamide oxygen. F2.57 is forming an 
aromatic-aromatic interaction with the 1,8-naphthyridine ring for all compounds.   
Residue F2.61 has a hydrophobic interaction with the 4-methyl cyclohexyl group.  
Residues I3.29, V3.32, M6.55, and L6.59 form a hydrophobic pocket in which part of the 
ligand sits.  For the antagonists, compounds 20, 21, and 26, the C-6 substituent extends 
down into the receptor far enough to block the “toggle switch” residue W6.48 from 
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changing its χ1 torsion angle from g+ to trans.  This prevents the receptor from 
undergoing the conformational change associated with receptor activation and G-protein 
coupling.  The agonists, compounds A1, A2, 5, and 17, bind to the receptor but cannot 
block W6.48 because they have smaller substituents at C-6.  As a result, W6.48 can 
change conformations along with F3.36 (see Introduction, Page 3) causing the ionic lock 
between TMH3 and TMH6 to break, and creating an intracellular opening for G-protein 
insertion.  All compounds have aromatic-aromatic interactions and hydrophobic 
interactions with the same set of residues.  Figure 14 shows compound A1, an agonist, 
docked in the receptor.  The dotted lines represent hydrogen bonds.  Figure 15 illustrates 
compound 26, an antagonist, docked in the receptor model.  Both agonists and 
antagonists interact with receptor in similar ways, the difference comes from the space 
occupied by the C-6 substituent on the antagonists.  Figure 16 shows the agonist A1 
binding to CB2 and how the absence of a substituent on C-6 allows for W6.48 to change 
conformations and activate the receptor for G-protein insertion.  Figure 17 shows the 
antagonist, 26 and how its large substituent on C-6 blocks the conformational change of 
W6.48. 
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Figure 14. Binding Model of Agonist, Compound A1 Docked into CB2.  The view is 
from extracellular with loops removed for clarity.  Pink residues are interacting via 
hydrophobic interactions, orange residues are interacting via aromatic-aromatic 
interactions, and green residues are hydrogen bonding. 
 
 
Figure 15. Binding Model of Antagonist, Compound 26 Docked into CB2.  The view is 
from extracellular with loops removed for clarity.  Pink residues are interacting via 
hydrophobic interactions, orange residues are interacting via aromatic-aromatic 
interactions, and green residues are hydrogen bonding. 
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Figure 16. Transmembrane View of Binding Model of Agonist, Compound A1 Docked 
into CB2.  The view is from the transmembrane region.  Pink residues are interacting via 
hydrophobic interactions, orange residues are interacting via aromatic-aromatic 
interactions, and green residues are hydrogen bonding.  The black arrow on W6.48 shows 
the path its χ1 torsion angle takes during activation. 
 
 
 
Figure 17. Transmembrane View of Binding Model of Antagonist, Compound 26 Docked 
into CB2.  The view is from the transmembrane region.  Pink residues are interacting via 
hydrophobic interactions, orange residues are interacting via aromatic-aromatic 
interactions, and green residues are hydrogen bonding.  The black arrow on W6.48 shows 
the path it needs to take to activate.  It is clear here that this change is blocked by the 
ligand. 
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Project 2: Aminoalkylindole Conformational Analysis 
 The unique conformers for the AAI compounds can be separated into two distinct 
classes.  For each AAI compound there is an s-cis conformation and an s-trans 
conformation.  The s-cis conformation places the naphthyridine ring over the indole ring 
and the carbonyl oxygen over the C-2 group, while the s-trans places the naphthyridine 
ring over the C-2 group and the carbonyl oxygen over the indole ring.  When the C-2 
group is a methyl the s-cis conformation is lower in energy than the s-trans.  Figure 18 
shows the s-cis and s-trans conformations for WIN55212-2 (which contains a C-2 
methyl).  It is also shows that the s-trans conformation for WIN55212-2 is 1.55 kcal/mol 
higher in energy.  When the C-2 group is a hydrogen, the s-trans is lower in energy.  
Analyzing the conformational search of JWH 120, which has a hydrogen at C-2 shows 
that the s-trans conformation is lower in energy.  Figure 19 shows the s-cis and s-trans 
conformations for JWH 120.  The JWH 120 s-cis conformation is 1.81 kcal/mol higher in 
energy.  JWH 120 is the only aminoalkylindole with a hydrogen at C-2 used in this study.  
As mentioned before, only the s-cis conformers were used to generate the pharmacophore 
model. 
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Figure 18. The s-cis and s-trans Conformations of WIN 55212-2.  The s-trans 
conformation is 1.55 kcal/mol higher in energy. 
 
 
 
Figure 19. The s-cis and s-trans Conformations of JWH 120.  The s-cis conformation is 
1.81 kcal/mol higher in energy. 
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 A high number of conformers arise due to the orientation of the naphthyl group 
and the dihedrals of the N-1 tail.  The N-1 tail prefers to be in an extended conformation, 
making the second bond in the tail assume an anti conformation.  There are four 
orientations the naphthyl group prefers to be in when the overall conformation is s-cis.  
For WIN 55212-2 the naphthyl group prefers to have it’s B ring (the ring not directly 
connected to the carbonyl carbon) and the carbonyl oxygen on the same side as the N-1 
tail.  To put both on the opposite side of the the N-1 tail costs 0.044 kcal/mol.  The other 
naphthyl ring conformations, put the B ring and the carbonyl oxygen on opposite sides.  
For the B ring to be on the opposite side as the N-1 tail and the carbonyl oxygen to be on 
the same side as the N-1 tail costs 1.31 kcal/mol.  The reverse, costs 1.36 kcal/mol.  The 
global minimum conformer for WIN 55212-2 has the carbonyl oxygen 21.3 ° out of plane 
with the indole ring.  These four conformations of the naphthyl group for WIN 55212-2 
are shown in Figure 20.  The other AAI compounds have the carbonyl oxygen slightly 
more out plane with the indole ring in their global mins ( 25° - 30°).  All of the other 
actives compounds prefer to have the B ring of the naphthyl group and the carbonyl 
oxygen on the opposite side of the indole ring as the N-1 tail.  To put both groups on the 
same side as the N-1 tail costs, 0.100 kcal/mol for TK-18, 0.094 kcal/mol for CBX 003, 
0.095 kcal/mol for CBX 004, and 0.452 kcal/mol for CBX 009.  Figure 21 shows the 
naphthyl group conformations for TK 18. 
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Figure 20. The Positions the Naphthyl Group Prefers to Assume in WIN 55212-2 and 
Energies. 
 
 
Figure 21. The Positions the Naphthyl Group Prefers to Assume in TK 18 and Energies. 
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 The inactive compound, CBX 008 (structure and binding data in Appendix 2 
Table 4), has its carbonyl oxygen 55.7° degrees out of plane with the indole ring.  The C-
2 trifluoromethyl group sterically hinders the oxygen from coming into plane.  This 
causes the naphthyl group to occupy space that the s-cis conformers of the other AAI 
compounds do not occupy.  Another inactive compoud, CBX 007, has a chlorine at C-4 
of the indole.  This Cl atom interferes with the naphthyl group when CBX 007 is in an s-
cis conformation.  This results in the carbonyl oxygen being 51° out of plane with the 
indole.  Another inactive compound, CBX 001, has a methoxy group at C-5 of the indole 
ring.  The methyl group prefers to point up towards C-4.  The carbonyl oxygen is only 
26° out of plane with the indole ring, similar to AAI compounds that bind.  However, 
CBX 001 may have steric clashes with  the receptor caused by the methoxy group at C-5. 
        
 CBX 007       CBX 001 
Figure 22. Structures of Inactive AAIs: CBX 007 and CBX 001 
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Amioalkylindole Pharmacophore Model 
 The final pharmacophore model (see Figure 23) has six features; four aromatic 
features, one hydrophobic feature, and one hydrogen bond acceptor feature.  Two of the 
aromatic features correspond to the indole rings (R7 and R8) and the other two 
correspond to the naphthyridine ring (R9 and R10).  The hydrophobic feature (H6) 
corresponds to the C-2 methyl group that is found on all of the actives and promotes the 
s-cis conformation.  The hydrogen bond acceptor feature (A3) corresponds to the 
carbonyl oxygen. Figure 23 shows the pharmacophore model from the side and from 
behind the indole ring.  Table 1 in Appendix 1gives the distances between the features in 
the model.  Table 2 in Appendix 1 gives the angles between the features in the model.  
Because PHASE places the N-1 tail hydrophobic feature in slightly different region of 
space for WIN 55212-2 compared to the other actives, no hydrophobic feature was able 
to be placed at the N-1 tail.  No analog has been tested to find the importance of a 
hydrophobic feature at the N-1 tail.  The pharmacophore model places the B ring of the 
naphthyl group and the carbonyl oxygen on the same side of the indole ring as the N-1 
tail.  This orientation matches WIN 55212-2’s global minimum conformation.  This 
agrees with the binding data because WIN 55212-2 has the highest affinity for the 
receptor (Ki = 27 pM).  Figure 24 shows WIN 55212-2 aligned to the pharmacophore 
model.  All the features of the model align well with WIN 55212-2’s global minimum 
conformation.  Figure 25 shows TK 18, another active compound, aligned to the model.  
The conformation of TK 18 that aligns the best is 0.108 kcal/mol higher in energy than 
the global minimum.  When aligning the model to the inactive compound it is expected to 
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not align well.  Figure 26 shows CBX 008 aligned to the model and how the naphthyl 
rings do not align well to those two aromatic features.  Also, the carbonyl oxygen is not 
aligned well with the hydrogen bond acceptor feature. 
 
Figure 23. Pharmacphore Model.  A) From the side view with distances B) Rotated 90° 
about the z-axis from image A to look behind the indole ring. 
38 
 
 
Figure 24. Pharmacophore Model Aligned to WIN 55212-2. A) Side view B) Rotated 90° 
about the z-axis from image A to look behind the indole ring. 
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Figure 25.  Pharmacophore Model Aligned to TK 18. A) Side view B) Rotated 90° about 
the z-axis from image A to look behind the indole ring. 
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Figure 26. Pharmacophore Model Aligned to CBX 008. A) Side view B) Rotated 90° 
about the z-axis from image A to look behind the indole ring. 
 
 
 The poor aligment for CBX 008 is due to the trifluoromethyl group that causes 
steric clashes with the carbonyl oxygen and pushes the oxygen 55.7° out of plane.  Figure 
27 shows how far out of plane the carbonyl oxygen is in CBX 008 compared to WIN 
55212-2. 
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Figure 27. WIN 55212-2 vs. CBX 008: Carbonyl Oxygen Out of Plane. 
 
 
Recommendations for Additional Analogs to be Tested 
 Having developed this first pharmacophore model for the AAI receptor, there are 
some analogs (not synthesized yet) that would help with a second generation model.  
When designing these analogs to test, it is important to not change too many groups at 
once.  Some AAI analogs that have already been made and tested, changed two groups at 
once and therefore it is not possible to attribute loss of binding to a single reason..  WIN 
55212-2 has the highest affinity for the receptor with a Ki of 27 pM.  What makes WIN 
55212-2 stand out as the best ligand should be further explored.  Some additional analogs 
could be tested to determine this.  The feature that WIN 55212-5 has that the other 
compounds do not is the heterocyclic ring fused to the indole ring.  The ether group in 
that ring may be hydrogen bonding with the receptor, thus increasing the affinity.  Table 
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1 shows two analogs that could be made and tested to determine the importance of that 
ether oxygen.  Analog 1 has a ketone group at the C-7 position of the indole ring, putting 
a hydrogen bond acceptor group in a similar region of space as WIN 55212-2 does, but 
removing the fused ring.  Analog 2 removes the ether oxygen from WIN 55212-2 and 
replaces it with a methylene group.  How these substituents affect the conformation of the 
N-1 tail would need to be explored as well.  Table 2 shows a set of analogs that could be 
made and compared to TK 18 (Ki 0.8 nM).  The importance of a hydrophobic group at N-
1 is not clear because there was no analog tested that did not have a hydrophobic group at 
N-1.  Existing analogs show that a methyl, ethyl, propyl, cyclopropyl, trifluoroethyl, and 
ethylmorpholino groups at N-1 all have affinity for the receptor.  Analog 3 has just a 
hydrogen at N-1, this analog would test if a hydrophobic group is necessary for binding.  
Analog 4 removes the six member ring of the indole to leave a pyrrole ring.  This would 
test the neccessity of the indole ring.  The ethylmorpholino ring at N-1 could be 
interacting via hydrogen bonding with the receptor or it could be interacting via 
hydrophobics interactions.  To probe the role of the ethylmorpholino ring in AAI binding, 
Analog 5 could be made with an N-1 ethyl cyclohexyl group.  The AAI compound 
Pravadoline is inactive at this receptor.  Is this due to the loss of the extra 6 member ring 
of the napthyl or because of the methoxy group at the C-4 position?  To test this, Analog 
6 could be made with a methoxy at C-4 of the naphthyl group.  Analog 7 has an 
anthracene group attached to the carbonyl carbon instead of a naphthyl group.  There is a 
methyl group at the C-6 position to mimic the methyl group at the C-4 position in TK 18. 
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Analog 7 would probe how large the binding site is and if increasing the aromatic groups 
increases affinity. 
 
Table 1. Analogs to be Tested from Parent Compound WIN 55212-2 
 
 
 
 
 
 
 
 
 
 
 
 
Parent Compound Analog 1 Analog 2 
WIN 55212-2 
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Table 2. Analogs to be Tested from Parent Compound TK 18 and Pravadoline 
Parent 
Compound 
Analog 3 Analog 4 Analog 5 Analog 6 Analog 7 Pravadoline 
TK 18
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CHAPTER IV 
CONCLUSION 
 
 
Project 1: 1,8-Naphthyridine Binding Model 
 Compounds from the 1,8-naphthyridine scaffold were developed in hopes of 
generating CB2 selective ligands.  Ligands were successfully developed that are selective 
for CB2, but some of these compounds act as agonists and some act as 
antagonists/inverse agonists.  A binding model was developed to explain the different 
activities.  The binding model shows that compounds with a substituent attached at the C-
6 position interferes with the toggle switch residues, W6.48 and F3.36, and prevents the 
receptor from assuming an active state conformation.  This prevents the G protein from 
inserting and therefore signaling cannot occur. 
Project 2: Aminoalkylindole Pharmacophore Model  
 Evidence for an unidentified receptor was found in HEK 293 and T98G 
astrocytoma cells.  This receptor binds aminoalkylindoles, but not other traditional CB 
ligands.  This suggests that the unidentified receptor is not a CB receptor or CB-like 
receptor.  This new receptor couples to Gi/o G-proteins and therefore is a GPCR.  A 
pharmacophore model for aminoalkylindoles binding to this new GPCR was developed 
based on the ligands that were available.  The pharmacophore model determined four 
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aromatic groups are important for binding, along with a hydrogen bond acceptor, and a 
hydrophobic feature. This model can hopefully provide insights for the development of 
additional ligands to study this new receptor.  In fact, several more AAI analogs are 
proposed here that should provide more information on the structural importance of key 
moieties found in some AAI compounds.  Once more ligands have been developed and 
tested; a 3D-QSAR model can be generated.  This would provide more details about the 
structural and electronic features that affect binding to this AAI receptor.
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APPENDIX A 
PHARMACOPHORE MODEL MEASUREMENTS 
Table 3. Distances between the features in the Pharmacophore Model 
Site1 Site2 Distance (Å) 
A3 H6 2.925 
A3 R7 3.418 
A3 R8 5.086 
A3 R9 4.082 
A3 R10 3.647 
H6 R7 2.67 
H6 R8 4.815 
H6 R9 6.901 
H6 R10 5.923 
R7 R8 2.153 
R7 R9 6.183 
R7 R10 4.858 
R8 R9 6.632 
R8 R10 5.215 
R9 R10 2.443 
 
Table 4. Angles between the features in the Pharmacophore Model 
Site1 Site2 Site3 Angle (°) 
H6 A3 R7 49 
H6 A3 R8 67.8 
H6 A3 R9 159.7 
H6 A3 R10 128.3 
R7 A3 R8 18.8 
R7 A3 R9 110.7 
R7 A3 R10 86.8 
R8 A3 R9 92 
R8 A3 R10 71.2 
R9 A3 R10 36.3 
A3 H6 R7 75.1 
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A3 H6 R8 78 
A3 H6 R9 11.8 
A3 H6 R10 28.9 
R7 H6 R8 3 
R7 H6 R9 63.3 
R7 H6 R10 54 
R8 H6 R9 66.2 
R8 H6 R10 57 
R9 H6 R10 20.2 
A3 R7 H6 55.8 
A3 R7 R8 130.5 
A3 R7 R9 38.1 
A3 R7 R10 48.6 
H6 R7 R8 173.2 
H6 R7 R9 94 
H6 R7 R10 99.7 
R8 R7 R9 92.4 
R8 R7 R10 87.1 
R9 R7 R10 21.6 
A3 R8 H6 34.2 
A3 R8 R7 30.7 
A3 R8 R9 38 
A3 R8 R10 41.4 
H6 R8 R7 3.8 
H6 R8 R9 72.2 
H6 R8 R10 72.3 
R7 R8 R9 68.6 
R7 R8 R10 68.5 
R9 R8 R10 19.5 
A3 R9 H6 8.5 
A3 R9 R7 31.1 
A3 R9 R8 50 
A3 R9 R10 62.1 
H6 R9 R7 22.7 
H6 R9 R8 41.6 
H6 R9 R10 56.7 
R7 R9 R8 18.9 
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R7 R9 R10 47 
R8 R9 R10 45.4 
A3 R10 H6 22.8 
A3 R10 R7 44.6 
A3 R10 R8 67.4 
A3 R10 R9 81.6 
H6 R10 R7 26.4 
H6 R10 R8 50.7 
H6 R10 R9 103.1 
R7 R10 R8 24.4 
R7 R10 R9 111.4 
R8 R10 R9 115.2 
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APPENDIX B 
TABLES OF COMPOUNDS 
Table 5. The compounds developed by Manera et al. with binding/activity data 
Compounds CB2 Binding 
Assay (nM) 
Ki              IC50 
β-Arrestin 2 
 
EC50/IC50 (nM) 
cAMP 
 
EC50/IC50 
(nM) 
A1 
 
1.90            2.89 17.53 28.0 
A2 
 
0.90            1.37 29.54 29.59 
5 
 
53.34      210.17 23.70 NA 
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Compounds CB2 Binding 
Assay (nM) 
Ki              IC50 
β-Arrestin 2 
 
EC50/IC50 (nM) 
cAMP 
 
EC50/IC50 
(nM) 
17 
 
1.36              5.35 21.83 20.58 
20 
 
0.18              0.72 31.59 NA 
21 
 
1.26              4.95 32.12 59.54 
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Compounds CB2 Binding 
Assay (nM) 
Ki              
IC50 
β-Arrestin 2 
 
EC50/IC50 
(nM) 
cAMP 
 
EC50/IC50 
(nM) 
26 
 
1.47        5.56 54.0 NA 
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Table 6. Aminoalkylindoles used to develop pharmacophore model and their binding 
affinities 
Compound Binding Affinity (Ki) 
WIN55212-2 
 
Biphasic displacement curve 
 
0.027 nM (0.0004  to 0.027) 
 
72 nM (54 to 8000) 
TK-18 
 
Biphasic Displacement Curve 
 
0.8 nM (0.39 to 1.5) 
 
90 nM (61 to 130) 
CBX-002 
 
Biphasic Displacement Curve 
 
10 nM (1.1 to 19) 
 
2300 nM (130 to 1800) 
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Compound Binding Affinity (Ki) 
CBX-003 
 
 
Biphasic Displacement Curve 
 
0.4 nM (0.12 to 0.43) 
 
382 nM (120 to 1300) 
CBX-004 
 
3.5 nM (1.0 to 12) 
CBX-005 
 
Biphasic Displacement Curve 
 
5.5 nM (0.15 to 200) 
 
2600 nM (16 to 41000 ) 
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Compound Binding Affinity (Ki) 
CBX-006 
 
113 nM (50 to 250) 
CBX-008 
 
972 nM (410 to 2300) 
CBX-009
 
 
1.8 nM (0.41 to 7.6) 
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Compound Binding Affinity (Ki) 
CBX-010 
 
118 nM (61 to 230) 
CBX-011 
 
Biphasic Displacement Curve 
 
5.8 nM (0.25 to 5.8) 
 
21000 nM (210 to 22000) 
JHW-015 
 
 
 
 
 
 
 
41 nM (31 to 54) 
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Compound Binding Affinity (Ki) 
JWH-120 
 
319 nM (120 to 850) 
JWH-148 
 
 
 
95 nM (49 to 180) 
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Compound Binding Affinity (Ki) 
Z Hydrogen Indene 
 
437 nM 
Z Methyl Indene 
 
466 nM 
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Compound Binding Affinity (Ki) 
E Hydrogen Indene 
 
3400 nM 
E Methyl Indene 
 
 
 
 
 
 
 
 
NA 
 
